DK2714916T3 - ABEADENOVIRUS AND HYBRID ADENOVIRUS VECTORS - Google Patents

ABEADENOVIRUS AND HYBRID ADENOVIRUS VECTORS Download PDF

Info

Publication number
DK2714916T3
DK2714916T3 DK12723726.1T DK12723726T DK2714916T3 DK 2714916 T3 DK2714916 T3 DK 2714916T3 DK 12723726 T DK12723726 T DK 12723726T DK 2714916 T3 DK2714916 T3 DK 2714916T3
Authority
DK
Denmark
Prior art keywords
vector
ady25
seq
sequence
antigen
Prior art date
Application number
DK12723726.1T
Other languages
Danish (da)
English (en)
Inventor
Matthew Douglas James Dicks
Matthew Guy Cottingham
Adrian Vivian Sinton Hill
Sarah Gilbert
Original Assignee
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford Innovation Ltd filed Critical Univ Oxford Innovation Ltd
Application granted granted Critical
Publication of DK2714916T3 publication Critical patent/DK2714916T3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0603Embryonic cells ; Embryoid bodies
    • C12N5/0606Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10021Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10041Use of virus, viral particle or viral elements as a vector
    • C12N2710/10042Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10041Use of virus, viral particle or viral elements as a vector
    • C12N2710/10044Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/20Pseudochromosomes, minichrosomosomes
    • C12N2800/204Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK12723726.1T 2011-05-25 2012-05-25 ABEADENOVIRUS AND HYBRID ADENOVIRUS VECTORS DK2714916T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1108879.6A GB201108879D0 (en) 2011-05-25 2011-05-25 Vector
PCT/GB2012/000467 WO2012172277A1 (en) 2011-05-25 2012-05-25 Simian adenovirus and hybrid adenoviral vectors

Publications (1)

Publication Number Publication Date
DK2714916T3 true DK2714916T3 (en) 2018-02-19

Family

ID=44279666

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12723726.1T DK2714916T3 (en) 2011-05-25 2012-05-25 ABEADENOVIRUS AND HYBRID ADENOVIRUS VECTORS

Country Status (16)

Country Link
US (4) US9714435B2 (OSRAM)
EP (2) EP2714916B1 (OSRAM)
JP (1) JP6230527B2 (OSRAM)
CN (1) CN103930551B (OSRAM)
AU (1) AU2012270144B2 (OSRAM)
BR (1) BR112013030222A2 (OSRAM)
CA (1) CA2837274C (OSRAM)
DK (1) DK2714916T3 (OSRAM)
ES (1) ES2659183T3 (OSRAM)
FR (1) FR21C1026I1 (OSRAM)
GB (1) GB201108879D0 (OSRAM)
NO (2) NO2714916T3 (OSRAM)
RU (1) RU2013152648A (OSRAM)
SG (2) SG10201604179VA (OSRAM)
WO (1) WO2012172277A1 (OSRAM)
ZA (1) ZA201309016B (OSRAM)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201108879D0 (en) * 2011-05-25 2011-07-06 Isis Innovation Vector
KR20150014505A (ko) * 2012-05-18 2015-02-06 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 아과 e 원숭이 아데노바이러스 a1302, a1320, a1331 및 a1337 및 이것들의 사용
JP6576326B2 (ja) 2013-03-14 2019-09-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍溶解性アデノウイルス組成物
GB201413530D0 (en) 2014-07-30 2014-09-10 Isis Innovation Treatment and prevention of malaria
WO2016198599A1 (en) * 2015-06-12 2016-12-15 Glaxosmithkline Biologicals S.A. Adenovirus polynucleotides and polypeptides
KR20220163505A (ko) 2016-02-23 2022-12-09 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
GB2549809C (en) * 2016-06-23 2022-11-30 Univ Oxford Innovation Ltd Vector
JP2019536468A (ja) 2016-12-12 2019-12-19 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍を標的にする合成アデノウイルスおよびその使用
CN106916851A (zh) * 2017-03-01 2017-07-04 广州恩宝生物医药科技有限公司 一种复制缺陷型人14型腺病毒载体及其制备方法和应用
WO2018167486A1 (en) 2017-03-15 2018-09-20 Oxford Biomedica (Uk) Limited Method
JP2020518648A (ja) 2017-05-08 2020-06-25 グリットストーン オンコロジー インコーポレイテッド アルファウイルス新生抗原ベクター
GB201708444D0 (en) 2017-05-26 2017-07-12 Univ Oxford Innovation Ltd Compositions and methods for inducing an immune response
BR112020013679A2 (pt) 2018-01-04 2020-12-01 Iconic Therapeutics, Inc. anticorpos de fator antitecidual, conjugados anticorpo-fármaco e métodos relacionados
AU2019251356B2 (en) 2018-04-09 2025-06-12 Salk Institute For Biological Studies Oncolytic adenovirus compositions with enhanced replication properties
GB201812647D0 (en) * 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer
GB201814141D0 (en) * 2018-08-30 2018-10-17 Univ Oxford Innovation Ltd Method and compositions for producing a virus
CN109797168A (zh) * 2018-09-28 2019-05-24 广州佰芮慷生物科技有限公司 一种重组腺病毒的表达载体SAd23-L
US12377138B2 (en) 2018-10-10 2025-08-05 Oxford University Innovation Limited Treatment and prevention of malaria
GB201818084D0 (en) 2018-11-06 2018-12-19 Univ Oxford Innovation Ltd Compositions and methods
CN109602901B (zh) * 2019-01-08 2022-05-27 成都迈科康生物科技有限公司 一种带状疱疹病毒疫苗及其制备方法和应用
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CN114828884A (zh) 2019-05-22 2022-07-29 埃利克斯疗法公司 用于疫苗的剂量方案
WO2020237027A1 (en) * 2019-05-22 2020-11-26 Gilead Sciences, Inc. Combination of a tlr7 modulating compound and an hiv vaccine
AU2020282369A1 (en) 2019-05-30 2022-01-20 Seattle Project Corp. Modified adenoviruses
HRP20241379T1 (hr) 2019-09-30 2024-12-20 Gilead Sciences, Inc. Cjepiva za hbv i postupci za liječenje hbv
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines
PH12022551208A1 (en) 2019-11-18 2023-04-24 Janssen Biotech Inc Vaccines based on mutant calr and jak2 and their uses
BR112022014808A2 (pt) 2020-01-31 2022-09-20 Beth Israel Deaconess Medical Ct Inc Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2
GB2594683A (en) 2020-02-17 2021-11-10 Vaxbio Ltd Vaccine
GB202003611D0 (en) 2020-03-12 2020-04-29 Univ Oxford Innovation Ltd Stabilised viral fusion proteins
EP4117723A1 (en) 2020-03-13 2023-01-18 Oxford University Innovation Limited Compositions and methods for inducing an immune response
RU2720614C9 (ru) * 2020-04-23 2021-02-09 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Иммунобиологическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
KR20230009445A (ko) 2020-05-11 2023-01-17 얀센 파마슈티칼즈, 인코포레이티드 안정화된 코로나바이러스 스파이크 단백질 융합 단백질
TWI867224B (zh) * 2020-06-08 2024-12-21 中央研究院 重組抗體或片段,以及其用途
IL299515A (en) 2020-06-29 2023-02-01 Janssen Vaccines & Prevention Bv Vaccine combination against respiratory syncytial virus infection
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022008438A1 (en) 2020-07-06 2022-01-13 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
GB2596820A (en) 2020-07-07 2022-01-12 Spicona Inc Combination vaccine
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
CN114845733A (zh) * 2020-08-22 2022-08-02 俄罗斯联邦卫生部的联邦国家预算机构“以名誉院士N.F.加马列亚命名的国家流行病学和微生物学研究中心” 抗严重急性呼吸综合征病毒SARS-CoV-2的表达载体
AU2020468491A1 (en) 2020-09-15 2023-04-27 Imperial College Innovations Limited Treatment of idiopathic pulmonary fibrosis
GB202016604D0 (en) 2020-10-20 2020-12-02 Univ Of Oxford Compositions and methods for inducing an immune response
GB202017673D0 (en) 2020-11-09 2020-12-23 Imperial College Innovations Ltd Treatment of pulmonary arterial hypertensive
TW202237164A (zh) * 2020-12-04 2022-10-01 美商磨石生物公司 組合物及其使用方法
GB202019455D0 (en) 2020-12-10 2021-01-27 Chancellor Masters And Scholars Of The Univ Of Oxford Method for producing virus
GB202019454D0 (en) 2020-12-10 2021-01-27 Chancellor Masters And Scholars Of The Univ Of Oxford Method for purifying virus
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
WO2022175477A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
AU2022224967A1 (en) 2021-02-23 2023-07-27 Janssen Vaccines & Prevention B.V. Trimer stabilizing hiv envelope protein mutation
US20240197859A1 (en) 2021-04-01 2024-06-20 Janssen Vaccines & Prevention B.V. Stabilized Pre-Fusion PIV3 F Proteins
GB202105277D0 (en) 2021-04-13 2021-05-26 Imperial College Innovations Ltd Signal peptides
WO2022234283A1 (en) 2021-05-07 2022-11-10 Astrazeneca Uk Limited Compositions and methods for inducing an immune response
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023026182A1 (en) 2021-08-24 2023-03-02 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023047348A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
WO2023047349A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
WO2023105221A1 (en) 2021-12-07 2023-06-15 Vaccitech (Uk) Limited Vaccine boost methods and compositions
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
EP4448802A1 (en) 2021-12-16 2024-10-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2023156505A1 (en) 2022-02-17 2023-08-24 Janssen Vaccines & Prevention B.V. Trimer stabilizing hiv envelope protein mutations r304v, n302m and t320l
WO2024061757A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
WO2024061759A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized coronavirus s proteins
EP4598939A1 (en) 2022-10-06 2025-08-13 MSD International Business GmbH Stabilized pre-fusion piv3 f proteins
WO2024084441A1 (en) 2022-10-19 2024-04-25 Aelix Therapeutics, S.L. Combination hiv vaccine
AU2023367778A1 (en) 2022-10-25 2025-05-01 Barinthus Biotherapeutics North America, Inc. Combination treatment regimes for treating cancer
GB202301244D0 (en) 2023-01-27 2023-03-15 Univ Oxford Innovation Ltd Vaccine
GB202303328D0 (en) 2023-03-07 2023-04-19 Imperial College Innovations Ltd Synthetic promoters
GB202305535D0 (en) 2023-04-14 2023-05-31 Imperial College Innovations Ltd Oligonucleotide decoy
WO2024218165A1 (en) 2023-04-17 2024-10-24 Barinthus Biotherapeutics (Uk) Limited Hpv viral vector vaccine
WO2025017540A1 (en) 2023-07-20 2025-01-23 Aelix Therapeutics, S.L. Method of treatment of hiv infection with vaccine
CN117089577B (zh) * 2023-08-21 2024-06-25 暨南大学 重组的猴腺病毒、病毒载体及构建方法
WO2025052130A1 (en) 2023-09-05 2025-03-13 Oxford University Innovation Limited Monoclonal antibody directed to reticulocyte-binding protein homologue 5 (pfrh5)
GB202400424D0 (en) 2024-01-11 2024-02-28 Cancer Research Tech Ltd Treatment and prevention of lung cancer
WO2025168946A1 (en) 2024-02-09 2025-08-14 Oxford University Innovation Limited Pfrh5 immunogen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3650939A (en) 1964-11-12 1972-03-21 Ppg Industries Inc Alkali chlorine cell
CA2271450A1 (en) 1999-05-12 2000-11-12 Stuart Energy Systems Inc. Hydrogen fuel replenishment process and apparatus
US20040136963A1 (en) 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
HU230364B1 (hu) * 2001-11-21 2016-03-29 The Trustees Of The University Of Pennsylvania Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
US20070205342A1 (en) 2002-01-23 2007-09-06 Edward Gabriel Slip drive for leveling devices
US7481858B2 (en) 2005-02-25 2009-01-27 Societe Bic Hydrogen generating fuel cell cartridges
DE602005017743D1 (de) * 2004-01-23 2009-12-31 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
US7617018B2 (en) 2004-10-18 2009-11-10 Innovative Design Solutions Platform attitude adjustment augmentation method and apparatus
US7178337B2 (en) 2004-12-23 2007-02-20 Tassilo Pflanz Power plant system for utilizing the heat energy of geothermal reservoirs
CN100578676C (zh) * 2005-01-12 2010-01-06 明基电通股份有限公司 可调式升降支撑装置
US20100143302A1 (en) * 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
WO2007110409A1 (en) * 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
EP2152889B1 (en) * 2007-05-29 2017-03-15 Nature Technology Corporation Vectors and methods for genetic immunization
CA2706258C (en) * 2007-11-28 2017-06-06 The Trustees Of The University Of Pennsylvania Simian subfamily e adenoviruses sadv-39, -25.2, -26, -30, -37, and -38 and uses thereof
DK2406288T3 (en) * 2009-03-10 2017-03-27 Baylor Res Inst ANTIGEN PRESENTING CELL-TARGETED VACCINES
GB201108879D0 (en) * 2011-05-25 2011-07-06 Isis Innovation Vector

Also Published As

Publication number Publication date
BR112013030222A2 (pt) 2016-12-06
EP3321367A3 (en) 2018-07-25
RU2013152648A (ru) 2015-06-27
GB201108879D0 (en) 2011-07-06
US9714435B2 (en) 2017-07-25
ZA201309016B (en) 2014-08-27
WO2012172277A4 (en) 2013-04-04
US11857640B2 (en) 2024-01-02
US20180000966A1 (en) 2018-01-04
FR21C1026I1 (fr) 2021-08-06
US10646587B2 (en) 2020-05-12
JP2014516536A (ja) 2014-07-17
ES2659183T3 (es) 2018-03-14
CA2837274A1 (en) 2012-12-20
US20150044766A1 (en) 2015-02-12
AU2012270144B2 (en) 2017-03-16
US20200360533A1 (en) 2020-11-19
US20240181078A1 (en) 2024-06-06
NO2714916T3 (OSRAM) 2018-06-09
SG10201604179VA (en) 2016-07-28
NO2021028I1 (no) 2021-07-07
EP2714916A1 (en) 2014-04-09
EP2714916B1 (en) 2018-01-10
WO2012172277A1 (en) 2012-12-20
SG195181A1 (en) 2013-12-30
JP6230527B2 (ja) 2017-11-15
CN103930551B (zh) 2017-05-24
CA2837274C (en) 2021-05-25
CN103930551A (zh) 2014-07-16
EP3321367A2 (en) 2018-05-16
EP3321367B1 (en) 2021-09-29

Similar Documents

Publication Publication Date Title
DK2714916T3 (en) ABEADENOVIRUS AND HYBRID ADENOVIRUS VECTORS
US12365920B2 (en) Adenoviral vector
AU2012270144A1 (en) Simian adenovirus and hybrid adenoviral vectors
CN108135991A (zh) 新型腺病毒
CN116323955A (zh) 通过crispr/cas介导的体内末端解析拯救重组腺病毒
HK40068020A (en) Adenoviral vector
HK40006989B (en) Adenoviral vector